421P Survival benefit of long-term (Beyond 2 years) atezolizumab in 1L ES-SCLC: Exploratory analysis of four phase III trials

N. Yang; F. Zeng; K. Ma; J. Huang; Q. Zhang; D. Hu

doi:10.1016/j.esmoop.2026.106735

March 17, 2026ESMO OpenOpen Access

421P Survival benefit of long-term (Beyond 2 years) atezolizumab in 1L ES-SCLC: Exploratory analysis of four phase III trials

View Full Paper

Ask AI

Bookmark

Share

Key Points

To investigate the long-term survival benefits of atezolizumab in early-stage small cell lung cancer (ES-SCLC).
Conducted a meta-analysis of four phase III trials
Compared efficacy and safety of PD-(L)1 inhibitors
Analyzed data from both Asian and non-Asian patient cohorts
Evaluated follow-up durations and patient population heterogeneity
Long-term use of atezolizumab shows comparable efficacy and safety to other PD-(L)1 inhibitors
Patients in various regions experience significant survival benefits
Meta-analysis confirms the need for more real-world evidence to support findings

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Meta-analysis demonstrates long-term efficacy of atezolizumab in ES-SCLC patients, suggesting benefits across regions.

Abstract

comparisons between subgroups difficult.Limitations of this meta-analysis included heterogeneity of study populations and follow-up durations. Conclusions:This meta-analysis demonstrates the comparability in efficacy and safety of PD-(L)1 inhibitors for 1L ES-SCLC in both Asian and non-Asian pts.More realworld evidence at the regional level will confirm long-term clinical benefits and tolerability in specific pt populations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/69be34f26e48c4981c6731e6 https://doi.org/10.1016/j.esmoop.2026.106735

View Full Paper

Ask AI

Bookmark

Share

421P Survival benefit of long-term (Beyond 2 years) atezolizumab in 1L ES-SCLC: Exploratory analysis of four phase III trials

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

421P Survival benefit of long-term (Beyond 2 years) atezolizumab in 1L ES-SCLC: Exploratory analysis of four phase III trials

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading